ATLANTA -- An investigational quadruple receptor agonist led to a substantial reduction in total body weight with minimal ...

Three new Cochrane reviews find evidence that GLP-1 drugs lead to clinically meaningful weight loss, though industry-funded ...

Eli Lilly and Company (NYSE: LLY) today announced positive results from a Phase 2 trial evaluating the safety and efficacy of ...

New science and innovative treatments offer hope in the fight against the global diabetes epidemic, with prevention and early ...

An investigational triple agonist that targets fibroblast growth factor 21, glucagon and GLP-1 receptors cut triglyceride ...

For the primary endpoint, Eczema Area and Severity Index (EASI) improved by 53-61% in a dose-dependent manner across the ...

Eli Lilly (LLY) said on Thursday that eloralintide, its experimental amylin receptor agonist for obesity, helped patients ...

A once-daily oral quadruple receptor agonist induced up to 13.8% weight loss at 13 weeks among adults with overweight or ...

Amylin receptor agonists are gaining attention as a new class of anti-obesity drugs. Eloralintide, a novel and selective long ...

The drug, given as a weekly subcutaneous injection, reduced both triglycerides and liver fat in the phase II trial.

Learn how 5-HT2A receptor agonists with psychedelic-like properties are assessed for receptor binding and behavioral efficacy ...